

		[1]	[2]	[3]	[4]	[5]	[6]	Present Study	
		EM. Borkowska	García-	SB Pattle	JA. Theurer	SM. McBride	T Suda		
		2021	2018	2017	2015	2014	2012	2021	
		Poland	Spain	Scotland	Indian	USA	Japan	Portugal	
		113	62	100	25	64	115	95	
Samples specimens		FFPE	biopsy Tumor	FFPE	biopsy Tumor	biopsy Tumor	biopsy Tumor	biopsy Tumor	
time collected		surgery	surgery	non	untreated	treated	surgical	diagnostic	
demographics									
gender	Male	86 (76%)	34 (55%)	63 (63%)	19 (76%)	21 (91%)	93 (81%)	70 (74%)	
	Female	27 (24%)	28 (45%)	37 (37%)	6 (24%)	2 (9%)	22 (19%)	25 (26%)	
range_age		42–91	33-90	non	<60y n=7	non	non		
mean_age		63	68	66	≥60y n=18	non	65	62	
risk factors									
consumptio	tobacco	84 (74%)	38 (61%)	47 (47%)	24 (96%)	13/23 (56.5%)	115 (100%)	66 (70%)	
	alcohol	62 (55%)	non	76 (76%)	non	non	non		
clinical parameters									
histologic diagnostic		HNSCC	HNSCC	HNSCC	HNSCC	HNSCC	HNSCC	HNSCC	
tumour location subsite	oral cavity	35 (31%)	non	0	11 (44%)	20 (31%)	31 (27%)	20 (21%)	
	oropharynx	30 (26%)	non	52 (52%)	8 (32%)	23 (36%)	25 (22%)	75 (79%)	
	larynx	48 (43%)	non	0	2 (8%)	8 (12%)	23 (20%)	0	
	Hypophary	0	non	48 (48%)	2 (8%)	5 (8%)	25 (22%)	0	
	Nasopharyn	0	non	0	2 (8%)	3 (5%)	11 (10%)	0	
	stage I		non		3 (12%)	non	12 (10%)	8 (8%)	
tumour stage	stage II	55 (49%)	non	57 (57%)	2 (8%)	non	23 (20%)	19 (20%)	
	stage III		non		2 (8%)	non	26 (23%)	26 (27%)	
	stage IV	58 (51%)	non	43 (43%)	18 (72%)	non	54 (47%)	40 (42%)	
HPV status	detected	26 (23%)	0	28 (28%)	non	non	non	27(28%)	
	not detected	87 (77%)	62 (100%)	70 (70%)	non	non	non	68 (72%)	
p16(+)	detected	11 (10%)	non	26 (26%)	8 (32%)	non	non	36 (38%)	
Evaluation PIK3CA gene									
PIK3CA-assay		qPCR	qPCR	qPCR	qPCR	qPCR	qPCR	RT-qPCR	
overall Frequency PIK3CA mutation		9 (8%)	11 (18%)	17 (17%)	4 (16 %)	10 (16%)	37 (32%)	37* (39%)	
copynumber/expression		non	non	yes	non	no	yes	no	
frequency PIK3CA per mutation type	exon 9	E542K	non	evaluated	non	1	2	evaluated	1
		E545K	non	evaluated	non	1	6	evaluated	2
		E545D	non	evaluated	non	1	1	evaluated	27
	exon 20	H1047R	9	evaluated	non	1	1	evaluated	1
		H1047L	non	non	non	non	0	evaluated	0
		oral cavity	3	non	non	2	1	9	8
frequency PIK3CA per HN subsite	oropharynx	0	non	14	2	6	10	29	
	larynx	6	non	non	0	1	8	0	
	Hypophary	non	non	3	0	0	9	0	
	Nasopharyn	non	non	non	0	2	1	0	
PIK3CA and HPV	mut	1	0	non	non	5	non	25	
	mut	8	11	non	non	1	non	12	
outcome									
OS		non	non	non	non	non	no association	no association	
DFS		non	non	non	non	non	non	better	
RFS		no correlation	non	non	non	non	non	non	

Legend:

\* 6 cases with 2 substitutions

non not described